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A B S T R A C T   
Nanobodies are single-domain antibody constructs derived from the variable regions of heavy chain only (VHH) 
camelid IgGs. Their small size and single gene format make them amenable to various molecular biology ap-
plications that require a protein affinity-based approach. These features, in addition to their high solubility, 
allows their periplasmic expression, extraction and purification in E. coli systems with relative ease, using 
standardized protocols. However, some Nanobodies are recalcitrant to periplasmic expression, extraction and 
purification within E. coli systems. To improve their expression would require either a change in the expression 
host, vector or an increased scale of expression, all of which entail an increase in the complexity of their 
expression, and production cost. However, as shown here, specific changes in the existing standard E. coli culture 
protocol, aimed at reducing breakdown of selective antibiotic pressure, increasing the initial culture inoculum 
and improving transport to the periplasmic space, rescued the expression of several such refractory Nanobodies. 
The periplasmic extraction protocol was also changed to ensure efficient osmolysis, prevent both protein 
degradation and prevent downstream chelation of Ni2+ ions during IMAC purification. Adoption of this protocol 
will lead to an improvement of the expression of Nanobodies in general, and specifically, those that are 
recalcitrant.   
1. Introduction 
Nanobodies are small (≈15 kDa) monomeric single-domain antibody 
constructs derived from the variable regions of either the heavy chain 
only IgGs derived from camelids (named VHH) and are similar to heavy 
chain only immunoglobulin new antigen receptor from nurse sharks 
(named VNAR) [1–4]. Despite their single domain nature, Nanobodies 
have been shown to be as specific as conventional monoclonal anti-
bodies, or their derivatives such as single-chain variable fragments 
(scFvs), and in some cases, even outperforming these [5–7]. Due to their 
small size and long CDR3 domains, Nanobodies have been shown to 
engage cryptic epitopes and targets that are not accessible to conven-
tional antibodies [8–13]. Additionally, unlike monoclonal antibodies, 
Nanobodies have a high thermal stability, resistance to pH and pro-
teases, as well as high solubility [14,15]. As single domain antibody 
constructs, their simple structure and small size makes them amenable 
to engineering for various molecular biology applications requiring a 
protein affinity-based approach [16–19]. Their single gene format as 
well as non-requirement for post-translational modifications allows 
their relatively easy periplasmic expression, extraction and purification 
in using E. coli systems using existing standardized protocols adapted 
from monoclonal or scFv expression [20–22]. 
Nanobodies are mostly over-expressed in E. coli systems [16,23]. As 
they contain a disulphide linkage between the complementarity deter-
mining regions (CDRs) 1 and 3, they require a suitable oxidizing envi-
ronment to correctly adopt their immunoglobulin fold [20,21,24,25]. 
This is not possible within the E. coli cytoplasm where the presence of 
thioredoxins contributes to a generally reducing environment [26–30]. 
Thus, expressed Nanobodies are directed to the E. coli periplasmic space. 
The E. coli periplasmic space is the region between the inner plasma-
lemma and the outer polysaccharide-rich coat of the gram-negative 
bacteria [31]. This space constitutes a multipurpose compartment 
which allows for several novel functions, amongst which is protein 
transport, folding, oxidation and quality control, much akin to the 
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eukaryotic endoplasmic reticulum [32,33]. The presence of an oxidative 
environment within the periplasm is the key reason for the directing of 
the over-expressed Nanobody there. The translocation of the Nanobody, 
synthesized in the cytoplasm, is achieved post-translationally via an 
N-terminal peptide signal targeting either the general secretory (Sec) or 
the twin-arginine-translocation (Tat) pathways [26,34–37]. Of the two, 
the Sec pathway is the more commonly targeted translocation mecha-
nism applied in our laboratory. To target this pathway, an N-terminal 
pelB leader signal derived from the 22-amino acid leader sequence of 
pectate lyase B of Erwinia carotovora is present on the expression cassette 
[38]. This signal is cleaved off by a periplasmic signal peptidase after the 
translocation process, leaving an authentic N-terminus devoid of an 
N-terminal methionine [38,39]. 
Periplasmic extraction of Nanobodies is done via osmotic shock [40]. 
The osmotic shock protocol was first described in experiments involving 
the extraction of periplasmic enzymes from E. coli [41,42]. In this pro-
cedure, cells are incubated in a hyperosmotic Tris-buffered sucrose so-
lution containing EDTA. The EDTA permeabilizes their outer 
membranes by chelation of divalent metal ions required for membrane 
stability, while the sucrose selectively concentrates in the periplasmic 
space. The pre-incubated cells are then exposed to a cold hypotonic 
solution leading to extrusion of the periplasmic contents through the 
peptidoglycan mesh via osmosis (hence ‘osmotic shock’) [43]. The 
periplasmic osmotic shock extraction system offers several advantages 
when compared to the cytoplasmic extraction of recombinant proteins 
from E. coli cells. Firstly, as previously stated, the periplasmic trans-
location removes the signal leader thus leaving an authentic N-terminal 
from the mature protein construct [38,39]. Secondly, the periplasmic 
extract contains only minimal amounts of cell wall, host derived proteins 
and cytoplasmic products. Thus, it is anticipated that the purity and 
yield of an over-expressed recombinant protein within the periplasmic 
extract obtained should be high. 
Some Nanobodies are atypically refractory to E. coli periplasmic 
expression, extraction and purification in the standard protocol. This is 
in great contrast to the standard expression and purification profiles 
reported for Nanobodies using this protocol. In situations where there is 
not sufficient diversity, or where the Nanobodies in question are of high 
value (e.g., with good binding affinities), then it becomes imperative to 
improve their expression, extraction and purification. Amongst the 
choices for improving the expression are either a change in the expres-
sion host, vector, or an increased scale of expression, all of which entail 
an increase in the complexity of their expression, not to mention the 
additional cost. In this study, the expression of several refractory 
Nanobodies was improved by simple modifications to the existing 
standard culture and extraction protocol. 
2. Methods 
2.1. Nanobody sequence analysis 
The plasmids (Fig. 1B; Supplementary Appendix 3 Fig. 1) with inserts 
encoding the different VHH gene sequences were obtained by growing 
out E. coli WK6 glycerol stocks from the CMIM laboratory at the VUB, 
Belgium. After an overnight pre-culture, plasmids were extracted from 
the cells using the GenElute™ Plasmid Miniprep Kit (Sigma Aldrich). 
PCR was carried out using plasmid-based primers (pHEN6C – M13F and 
M13R) to confirm insertion. Sanger sequencing was subsequently car-
ried out on the extracted plasmids using the same primer sets for each 
plasmid. 
Selected colonies showing correctly sized VHH inserts in the proper 
orientation and translating into an open reading frame encoding VHH/ 
Nanobody protein as simulated by CLC Main WorkBench (Qiagen) were 
approved for production. Glycerol stocks were prepared by adding 500 
μL of 50% glycerol to 500 μL of overnight culture in LB supplemented 
with 100 μg mL− 1 ampicillin and 0.1% glucose. These were stored at 
− 80 ◦C for future production of Nanobodies. 
Fig. 1. (A) IMGT alignment of select translated cDNA from Sanger sequencing of Nanobody gene insertions within the pHEN6C plasmid using primer M13RP and 
M13FP: The IMGT numbering system for variable regions of immunoglobulins relies on the high conservation of the structure of the variable region and denotes 
framework regions as FR and complementarity determining regions as CDR. Thus, FR1 - IMGT refers to position 1–26, FR2 - IMGT to 39–55, FR3 - IMGT to 66–104 
and FR4-IMGT to 118 – 128. Accordingly, CDR1 – IMGT refers to position 27 – 38, CDR2 – IMGT to 56 – 65 and CDR3 – IMGT to position 105 – 117. To maintain the 
positions, in light of CDR variability, gaps are introduced within the CDRs as utilized in 2-D graphical representations (designated as IMGT Colliers de Perles) [48,49] 
and in 3D structures in the IMGT/3D structure [50]. Thus, in a sequence alignment, gaps in the CDR1-IMGT (less than 12 residues long) and the CDR2-IMGT (less 
than 10 residues long) are put from the ‘top’ of the CDR-IMGT loops. Gaps in the CDR3-IMGT (basic length of 13 residues) are introduced in the same way when there 
are less than 13 residues. When there are more than 13 residues, additional positions are introduced between position 111 and 112 and labelled with whole numbers 
as seen in the alignment at A above. (B) The pHEN6C plasmid map indicating the positions of the M13RP and M13FP primers. 
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2.2. ExPASy analysis 
Using the derived, and confirmed VHH gene sequences, open reading 
frames were then characterized in silico using the online ProtParam tool, 
ExPASy: (https://web.expasy.org/protparam/). 
Molecular weight, pI, instability index and the extinction coefficient 
were calculated, based on the Nanobody sequences. 
2.3. Production and extraction using standard expression protocol 
Standard expression of the Nanobodies was carried out using the 
protocol as previously described [44]. A detailed protocol can be found 
in Appendix 1 in the Supplementary information. 
Briefly, pre-cultures (per Nanobody) were prepared by inoculation 
from glycerol stocks into LB media (10 mL max per 50 mL sterile conical 
bottomed tubes (BD Biosciences)) supplemented with a final concen-
tration of 100 μg mL− 1 ampicillin (Duchefa Biochemie), 2 mM MgCl2 
(Sigma Aldrich) and 0.1% glucose (Duchefa Biochemie). These pre- 
cultures (approximately 2 tubes per Nanobody) were incubated over-
night at 37 ◦C with aeration (200 rpm). 
The main culture (5 L per Nanobody) was started by inoculating 15 
baffled flasks (each with a capacity of 1 L) each containing 330 mL of TB 
medium supplemented with a final concentration of 100 μg mL− 1 
ampicillin, 0.1% glucose and 2 mM MgCl2 with a 330-fold dilution of the 
pre-culture i.e., 1 mL pre-culture per 330 mL of TB media. The culture 
was then incubated at 37 ◦C with aeration (200 rpm max) until an op-
tical density at 600 nm (OD600) = 0.6–0.8 was achieved. The incubation 
temperature was then lowered to 28 ◦C. 
Nanobody expression was induced by addition of 1 mM IPTG 
(Duchefa Biochemie) followed by incubation with aeration (200 rpm 
max) for ≥ 16 h. Cells were pelleted by centrifugation (11,305 g, 10 min, 
at 14 ◦C) and the periplasmic proteins extracted by osmotic shock via 
addition of ice-cold TES buffer (4 mL TES/330 mL of culture) for 6 h 
while shaking, followed by addition of ice-cold TES/4 buffer (8 mL TES/ 
4 for 330 mL of culture) and overnight incubation on ice while shaking 
at 200 rpm and 4 ◦C. To saturate the EDTA within the TES buffer, 2 mM 
MgCl2 (Sigma Aldrich) was added to the suspension (300 μL 2 M MgCl2 
for 330 mL of culture). The periplasmic extract (supernatant) was har-
vested by centrifugation (11,305 g; 30 min, at 4 ◦C) and kept aside for 
purification. The extraction protocol was then repeated on the resus-
pended cell pellets for a second time, but with reduced TES (2 h) and 
TES/4 (4 h) incubation times. 
2.4. Production and extraction using modified expression protocol 
In a bid to achieve an increased Nanobody yield production, a 
modified protocol was run. In this protocol, several factors i.e., culture 
media, pre-culture temperature, culture time, culture temperature and 
extraction methods, were changed (Table 1& Appendix 2). The glycerol 
stocks used remained the same. 
Briefly, pre-cultures (per Nanobody) were prepared by inoculation 
from the glycerol stock into 150 mL 2xTY supplemented with a final 
concentration of 100 μg mL− 1 ampicillin, 2 mM MgCl2 and 0.5% 
glucose. These pre-cultures were incubated overnight at 30 ◦C with 
aeration (200 rpm). The pre-cultures were harvested by centrifuging 
(3000 g, 10 min, at 20 ◦C) in sterile 50 mL conical bottomed tubes (BD 
Biosciences), and the supernatant discarded. The pellet was then 
resuspended in 30 mL 2xTY media supplemented with 100 μg mL− 1 
ampicillin and 0.5% glucose. 
The main culture (5 L per Nanobody) was started by inoculating 15 
baffled flasks (each with a capacity of 1 L) each containing 330 mL of 
2xTY medium supplemented with a final concentration of 100 μg mL− 1 
ampicillin, 0.5% glucose and 2 mM MgCl2 with 2 mL of the dissolved 
pre-culture pellet. The culture was then incubated at 37 ◦C with aeration 
(220 rpm max) until an optical density at 600 nm (OD600) = 0.6–0.8 was 
achieved. 
Nanobody expression was then induced at the same temperature 
(37 ◦C) by addition of 0.25 mM IPTG followed by incubation with 
aeration (220 rpm max) for 4 h. Cells were pelleted by centrifugation 
(11,305 g, 10 min, at 14 ◦C) and the periplasmic proteins extracted by 
osmotic shock via addition of ice-cold TES buffer (4 mL TES/330 mL of 
culture) overnight hours while shaking at 200 rpm and 4 ◦C. Lysozyme 
(0.5–1 mg per liter of bacterial culture) and DNAse (10 μg per liter of 
bacterial culture) were supplemented in the TES. The following day, 
osmotic shock was applied by addition of ice-cold 5 mM MgSO4 (8 mL 
per 330 mL of culture) for 2 h. The periplasmic extract (supernatant) was 
harvested by centrifugation (11,305 g; 30 min, 4 ◦C) and kept aside for 
purification. The extraction protocol was then repeated on the resus-
pended cell pellets for a second time, but with reduced TES (1 h) and ice- 
cold 5 mM MgCl2 (2 h) incubation times. 
2.5. Purification of extracted Nanobodies 
A HIS-select nickel affinity gel (Sigma Aldrich) was prepared by 
washing 2X with Milli-Q H2O by centrifugation at 353g for 7 min at 
20 ◦C. A third wash with phosphate binding buffer {22 mM NaH2-
PO4⋅H2O & 77 mM anhydrous Na2HPO4, 500 mM NaCl (pH 7.4)} or PBS 
containing 500 mM NaCl, was carried out at the same centrifugation 
conditions. The HIS-select nickel affinity gel was then incubated with 
the periplasmic extract at room temperature for 1 h with gentle shaking. 
In the meantime, a PD-10 column was prepared, and the column 
loaded with 5 mL of phosphate binding buffer to ensure free flow of 
buffer through the filter. The column was packed with the loaded HIS- 
select nickel affinity gel beads and drained by gravity. The unbound 
proteins were washed off the gel matrix with 20 column volumes of 
phosphate binding buffer. 
The bound His-tagged Nanobodies were eluted with stepwise addi-
tion of 1 mL 1 M imidazole buffer (to a total amount of 5 mL per 1 mL of 
His-Select nickel affinity gel beads) in PBS containing 500 mM NaCl and 
1 M imidazole (Sigma Aldrich) (pH 7.5). Aliquots were obtained from 
the fractions, then processed for SDS-PAGE and western blot analysis. 
The protein concentrations were estimated by measuring the absorbance 
at 280 nm (A280) on a NanoDrop ND-1000 spectrophotometer (Isogene) 
and applying the extinction coefficient. Fractions containing the Nano-
body of interest as visualized by SDS-PAGE were pooled and kept aside 
for further purification. 
The affinity purified histidine tagged Nanobodies were further pu-
rified by size exclusion gel filtration to separate out any remaining co- 
purifying contaminants. For the gel filtration, a Superdex 75 (S75) 10 
mm/300 mm (=~24 mL) or 16 mm/60 cm (=~120 mL) column (GE 
Healthcare) was pre-equilibrated with at least one column volume of 
phosphate buffered Saline (PBS) buffer {with 500 mM NaCl (pH 7.4)} on 
an Akta Explorer platform (GE Healthcare) or a BioRad NGC (BioRad). 
Aliquots were obtained from peak fractions, then processed for SDS- 
PAGE and western blot analysis. Fractions containing the Nanobody of 
interest were pooled, and absorbance at 280 nm (Abs280) measured with 
Table 1 
Comparison between the standard and modified expression protocols for 
Nanobody® production.   
Standard Protocol Modified 
Protocol 
Media used Terrific Broth 2xTY 
Pre-culture temperature 37 ◦C 30 ◦C 
Pre-culture/Culture ratio 1:300 1:30 
IPTG concentration used 1 mM 0.25 mM 
Culture temperature after induction 28 ◦C 37 ◦C 
Culture time after induction >14 h Max 4 h 
Osmotic shock after TES TES/4 (4-fold diluted 
TES) 
5 mM MgSO4 
IMAC column volume (per liter of 
culture) 
1 mL 0.5 mL  
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a NanoDrop ND-1000 spectrophotometer (Isogene). The protein con-
centration was then estimated using their extinction coefficient. These 
were then concentrated using Vivaspin protein concentrator columns 
with a 5000 Da MW Cut-Off (Sartorius) and stored at 4 ◦C. 
2.6. Quality control of expressed nanobodies using SDS-PAGE, western 
blotting and thermoflour analysis 
2.6.1. SDS-PAGE analysis 
Aliquots taken at different steps of the expression and purification 
protocol were subjected to SDS-PAGE analysis [45]to visualize the 
expression profile as well as the purification progress. Aliquots of 1 mL 
of the bacterial cultures taken from pre-cultures, before induction, and 
after overnight incubation of the induced culture were used. The sam-
ples were centrifuged for 3 min at maximum RPM and pellets 
re-suspended in 45 μL of water (filtered and sterilized). These were then 
boiled for 5 min at > 90 ◦C and subsequently stored at 4 ◦C. Prior to 
loading on SDS- PAGE, the samples were normalized to an OD600 of 0.25 
by appropriate dilution in Milli-Q water (filtered and sterilized), then 
boiled a second time at > 90 ◦C for 10 min with 25 μL of NuPage LDS 
sample buffer (4 X, supplemented with 50 mM DTT) in a total SDS-PAGE 
sample volume of 100 μL. All samples for SDS-PAGE analysis were 
loaded in duplicate at max 30 μL per well on a 10% acrylamide gel 
(BioRad Criterion XT 10% Bis-Tris precast gel). Gel electrophoresis was 
performed in 1 X MES buffer at 150 V until sufficient migration had 
occurred. Protein bands were visualized by staining with Coomassie 
Brilliant Blue R250 and molecular masses determined by estimation in 
comparison to the PageRuler Prestained Protein Molecular Weight 
Marker (ThermoFisher). 
2.6.2. Western blotting 
Western blotting was performed as described previously [46]. 
Briefly, the proteins were transferred from the electrophoresed poly-
acrylamide gel to either methanol - activated PVDF (ThermoFisher) or 
nitrocellulose with 0.45 μm pores (Amersham) membranes using a 
Bio-Rad wet transfer system with a tris-glycine buffer supplemented 
with methanol. The transfer process was carried out at 100 V for 1 h at 
room temperature with cooling provided by using a cooling cassette 
(previously stored at − 80 ◦C) inserted in the wet transfer system and a 
magnetic stirring bar for circulation. 
The membranes were blocked overnight at 4 ◦C in 5% BSA in PBS 
with shaking and subsequently washed 3 times with PBS-Tween 20 
(0.1%). For detection of the Nanobodies, 2.5 μL of the primary antibody 
(biotinylated mouse anti-His (ThermoFisher)) in 20 mL of 5% BSA in 
PBS was added to the membrane with an incubation of 1 h at room 
temperature. The membrane was then washed 3 times with PBS-Tween 
20 (0.1%), with 5 min per wash before being incubated for 1 h with 2.5 
μL of the secondary ligand (Streptavidin conjugated with Horseradish 
peroxidase (ThermoFisher)) in 20 mL of 5% BSA in PBS. After the in-
cubation, the membrane was again washed 3 times with PBS-Tween 20 
(0.1%), with 5 min per wash. The blot was developed chromogenically 
with the Pierce CN/DAB substrate kit (ThermoFisher). 
2.6.3. Differential scanning fluorimetry 
The thermostability of select monovalent Nanobodies was measured 
by differential scanning fluorimetry (Thermofluor) on a real-time PCR 
machine (Applied Biosystems 7500), in a 96-well plate format with a 
final volume of 25 μL in each well. For the buffer blank, 2 μL of 25 X 
SYPRO orange dye (Life Technologies) was mixed with 23 μL of PBS 
buffer (containing 500 mM NaCl (pH 7.4)). For the Nanobody® samples, 
2 μL of 25X SYPRO orange dye (Life Technologies) was mixed with 25 μL 
of the Nanobody® of interest at a final concentration of at least 0.4 mg 
mL− 1 in PBS buffer containing 500 mM NaCl (pH 7.4)). Data for all 
samples were collected in triplicate. The fluorescence was measured 
with increasing temperature, starting at 5 ◦C, and increasing the tem-
perature by 0.5 ◦C per minute up to 95 ◦C. To obtain buffer-corrected 
fluorescence signals for each Nanobody, the averaged buffer data set 
was subtracted from the averaged protein data set. The buffer-corrected 
fluorescence signal (F) was plotted as a function of temperature (T) and 
fitted with the Boltzmann sigmoidal function to obtain the melting 
temperature (Tm) using the equation 
F =F0 +
Fmax − F0
1 + eTm − Ta 
Where F0 and Fmax are the lowest (pre-transitional) and the highest 
(post-transitional) buffer corrected fluorescence signals (expressed in 
AU) and α is the change in T corresponding to the most significant 
change in F (also called the slope of the transition region, expressed in 
AU/◦C) [47]. 
3. Results 
In total, 6 Nanobodies were expressed using the modified protocol 
(Table 1). Three of them, Nb 1174, 1175 and 1176 were expressed with 
both standard and modified protocol in a comparative manner. The 
other three, Nb SH-75, Nb 60 and Nb 2RS15d were expressed with only 
the modified protocol, with the previous yields from the standard 
expression protocol indicated as reported. 
The Sanger - sequenced and translated cDNA sequences of three 
selected monovalent Nanobodies (Nbs) indicated that they were inserted 
in the correct orientation and open reading frame within their expres-
sion pHEN6C plasmid (Fig. 1A and B). 
Additionally, the three Nbs were confirmed to have the VHH hall-
mark amino acid substitutions in framework 2 (V37F, G44E, L45R and 
W47X) in accordance to Kabat/IMGT numbering (Fig. 1A.) [51,52]. The 
three Nanobody cDNA sequences also displayed the characteristic 
cysteine residues at positions 22 and 106 necessary for formation of a 
disulfide bridge between the Framework 1 and Framework 3 regions [4, 
53]. 
Global protein parameters for the Nanobodies were derived in silico 
using the Protparam tool [54] from Expasy resource portal (Table 2).. 
The six monovalent Nanobodies were then over-expressed in E. coli 
WK6 cells. The over-expression of the comparatively prepared three 
(1174, 1175 & 1176) using the standard operating protocol in com-
parison to the modified expression protocol did not appear to have 
significant differences as judged by the polyacrylamide gel profiles 
generated. (Fig. 2A.&B). In western blot though, the over-expression of 
the test Nanobodies (Nb 60, Nb SH-75 & Nb 2Rs15d) can be seen 
increasing over the sampling period (Supplementary Appendix 3 Fig. 2). 
However, upon purification after extraction via osmotic shock, there 
were changes observed in the gel profile between the two protocols for 
the comparatively run three Nanobodies (1174, 1175 & 1176). In 
particular, the second elution step (Elution 2) of the IMAC from the 
modified protocol appeared to have much more contaminants than of 
the similar step in the standard protocol. 
After IMAC, size exclusion chromatography is typically used as a 
secondary purification step for purification of Nanobodies. At this point, 
all the monovalent Nanobodies, when expressed with the standard 
protocol, could not be purified using the preparative large-scale SEC as 
their yields were too low. This meant that to achieve the polishing step, a 
smaller SEC column (S75 10 mm/300 mm (=~24 mL)) was used 
(Fig. 3A.). This translated to a lower final yield of pure Nanobodies. In 
comparison, the same Nanobodies, when produced via the modified 
protocol, gave higher yield, therefore meaning that to achieve the size 
exclusion purification step, a larger scale of preparative column (16 
mm/60 cm (=~120 mL)) could be utilized (Fig. 3B.). 
To measure the yields comparatively, the pure protein yield (in 
milligrams) per liter of culture used was calculated (Table 3). It was 
observed that there was at least a 3-fold increase in the yield of two of 
the comparatively prepared refractory Nanobodies (Nb 1174 and 1176). 
In one of the test cases, Nb_60, there was a 9-fold increase in the 
expression. 
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Table 2 
Nanobodies properties as estimated using the Protparam tool (https://web.expasy.org/protparam/) from the Expasy resource portal.*Test cases that were previously 
shown to be refractory, kindly provided by internal collaborators, see Acknowledgements.  
Protein Vector No of residues pI Molecular Weight (kDa) Extinction coefficient Abs 0.1% (1 g/L) 
Nb_ 1174 pHEN6c 134 7.9 14.5 26150 1.81 
Nb_ 1175 pHEN6c 134 8.6 14.6 37025 2.53 
Nb_ 1176 pHEN6c 132 8.4 14.8 30620 2.067 
*Nb_ 60 pHEN6c 146 5.0 15.9 41620 2.60 
*Nb_ SH75 pMECs 143 6.7 15.54 37610 2.42 
*Nb_2Rs15d-myc pHEN25 136 7.3 14.89 25690 1.73  
Fig. 2. Expression and IMAC purification Coomassie-stained polyacrylamide gel profiles for over-expressed Nanobodies 1174, 1175 & 1176. Panel A gives the 
profiles for over-expression with the standard protocol, while panel B gives the profiles for over-expression with the modified protocol. 
Fig. 3. Size exclusion chromatography of IMAC purified Nanobodies 1174, 1175 & 1176. Panel A indicates the purification of Nanobodies from standard expression 
protocol, while B indicates purification from the modified expression protocol. Inset within each curve, are the polyacrylamide gel (C) and western blot (W) profile 
for each purified Nanobody. Here a difference in yield is observed, as the panel A represents the curves from the smaller SEC column (S75 10 mm/300 mm (=~24 
mL)) thus giving lower yields, while panel B represents the curves from the larger preparative SEC column (S75 16 mm/60 cm (=~120 mL)) thus giving 
higher yields. 
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Differential scanning fluorimetry of the Nanobodies did not reveal 
significant changes in the melting temperatures (Fig. 4 A &B). 
4. Discussion 
Nanobodies are recombinantly produced small antigen binding do-
mains derived from the variable regions (VHHs) of camelid heavy-chain 
only antibodies (Hcab) [55,56]. They are mostly expressed in the pro-
karyotic expression host, E. coli, using well-established standard oper-
ating protocols [16,23,44]. 
Due to their requirement for proper disulphide linkage between their 
CDR1 and CDR3, folding of Nanobodies occurs primarily within the 
E. coli periplasmic space [20,25]. However, their transcription and 
translation occurs within the cytoplasm. Therefore, the folding protein 
needs to be translocated post-translationally to the periplasmic space via 
the general secretory pathway i.e., the Sec translocon [35]. 
Post-translational translocation to the periplasm is made possible via the 
hydrophobic pelB secretion signal on the N-terminus of the construct 
[38]. Once the nascent protein emerges from the ribosome, it binds to 
the trigger factor, followed by the binding of Sec B then Sec A [36,57]. 
This complex of SecA bound preproteins is then bound by the SecYEG 
translocase, which initiates the translocation process [35,36,57]. Thus, 
prior to translocation, preproteins must be maintained in an export 
competent conformation in the cytoplasm, which is thought to be a 
protease sensitive, loosely folded structure [35,36,39,57]. 
Variable antibody (Vab) fragments have been successfully expressed 
in E. coli using induction at high temperatures [58]. However, the 
standard Nanobody protocol is designed for IPTG induced protein 
expression at 28 ◦C [23,44]. While this enhances the expression of the 
proteins, and minimizes proteolytic degradation, efficient translocation 
to the correct folding environment can be hindered at this low temper-
ature. This is exacerbated when the recombinant protein is very effi-
ciently expressed by an induction step, quickly overwhelming the cell’s 
capacity to maintain the protein in an unfolded export competent state 
before periplasmic translocation. This subsequently leads to an accu-
mulation of expressed protein in the cytoplasm, mostly in a 
translocation-incompetent state, with the concomitant poor periplasmic 
yields. Previous work in our laboratory has established that the poor 
yield of such refractory Nanobodies can be resolved partially by freeze 
thawing the derived cell pellets, yielding dramatically higher amounts of 
proteins. Thus, poor yield exhibited by these Nanobodies can be 
attributed to the failure to translocate from the cytoplasm leading to 
their poor periplasmic extraction and purification profiles. However, as 
the freeze-thaw methods entails cell breakage, there are concerns about 
the folding state of the Nanobodies, proteolytic damage, as well as the 
presence of the un-cleaved signal peptide. We hypothesized that 
providing a higher expression temperature i.e., 37 ◦C would lead to 
improved periplasmic translocation and therefore better extraction and 
purification profiles. Due to the chance of increased degradative pro-
teolytic activity at 37 ◦C within the periplasm, in addition to heightened 
breakdown of the selective antibiotic pressure, we empirically optimized 
the expression time down from the normal overnight expression (>16 h) 
to 4 h. 
The Nanobody starting stock (preculture) of E. coli containing our 
recombinant Nanobody gene was grown atypically, at a low tempera-
ture (25–30 ◦C) and in a large volume for an eventual low pre-culture-to- 
culture volume ratio (1:30). In contrast, the typical Nanobody pre-
culture is grown at 37 ◦C and with an eventual high pre-culture-to- 
culture volume ratio (1:300). The reason for this change was two-fold. 
Firstly, the secretion of beta-lactamase, the enzyme responsible for 
antibiotic selectivity, was reduced at these low temperatures. The 
enzyme is translocated co-translationally by the Sec translocon from the 
cytoplasm to the periplasm. Therefore, using the standard pre-culture 
Table 3 
Nanobodies have an increased yield per liter of culture after the modification of 
the expression SOP. Nanobodies that were refractory to expression had at least a 
threefold increase in extracted and purified protein. *(The yield of the non- 
refractory Nanobody y. i.e., Nb 1175 did not change).#(These Nanobodies 
were expressed as test cases for the modified protocol. Further information on 
their vectors and purification is provided in the supplementary).  
Protein Vector Yield (mg/liter of 
culture) after 
Standard SOP 





Nb_ 1174 pHEN6c 0.7 4.3 6 
Nb_ 1175 pHEN6c 5 5.6 1* 
Nb_ 1176 pHEN6c 0.5 1.4 3 
#Nb_ 60 pHEN6c 0.25 2.21 9 
#Nb_ SH75 pMECs 0.6 1.14 2 
#Nb_2Rs15d- 
myc 
pHEN25 2 4.49 2  
Fig. 4. Graphs illustrating the thermal shift assay (Thermofluor) results for select monovalent Nanobodies before and after using the modified expression and 
extraction SOP. Results do not indicate a significant change in the melting temperature (Tm), thus showing that the protein proteins’ thermal properties are not 
changed by using the modified SOP. Measurements were done in triplicate and corrected for the buffer baseline, leading to the data points shown in black. A non- 
linear Boltzmann-Sigmoidal curve is fitted onto the data (red line). The Tm is calculated as the temperature where half of the hydrophobic residues are exposed. 
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temperature of 37 ◦C, the enzyme is efficiently translocated to the 
periplasm for maturation and secretion. This means that, over the course 
of a typical overnight pre-culture, the selective antibiotic pressure 
applied on the cells greatly diminishes. Further after the overnight in-
cubation, the pre-culture is typically diluted to a 1:300 preculture-to- 
culture volume ratio. However, the enzyme secreted over the over-
night incubation is also transferred to the new sub-culture thereby 
already diminishing selective pressure from the antibiotic used. We 
resolved the enzyme carry-over problem as mentioned above, by 
growing a large volume of the pre-culture, then centrifuging it to remove 
the enzyme containing supernatant. It was necessary to grow large pre- 
culture volume overnight, to achieve enough cells for the main culture. 
The pellet from the pre-culture centrifugation step was then resus-
pended in a smaller volume of culture medium before inoculation. This 
ensured a low ratio of pre-culture to culture and limited transfer of the 
overnight secreted beta-lactamase to the main culture. 
Extraction of the expressed Nanobodies within the periplasm is 
achieved by osmotic shock [23,44]. The osmotic shock is achieved by 
initially pre-incubating cells with a hyperosmotic Tris-EDTA-sucrose 
(TES) buffer. To achieve maximum release of proteins from the peri-
plasm, the osmotic shock requires cold conditions [41,42,59]. Under 
typical circumstances, this is then followed by addition of a cold 
four-fold diluted TES solution (TES/4). In this study, we found that the 
use of a dilute and ice-cold solution of magnesium sulfate (5 mM 
MgSO4), achieved the same effect as the TES/4. We postulated that the 
use of MgSO4 to extract the Nanobodies via osmotic shock would serve 
the purpose of complexing the EDTA within the TES, therefore avoiding 
chelation of the Ni2+ ions during the subsequent IMAC. In line with 
literature, we also used lysozyme and DNAse during the osmotic shock 
to enhance the periplasmic yield of the refractory Nanobodies [41,42]. 
However, we do not deem the addition of lysozyme to be necessary, for 
two reasons. The first is that for a reduction in costs and complexity, the 
procedure must be as simple as possible in comparison to the original 
protocol. Secondly, if the Nanobodies are over-expressed and present in 
the periplasm in adequately high concentrations, then gentle resus-
pension of the cells by shaking during the osmotic shock is adequate for 
their release from the periplasm. The resuspension of cells by gentle 
agitation is necessary to avoid the breakage of the spheroblasts, leading 
to chromosomal DNA contamination of the periplasmic extract. This 
then leads to a fouling during the downstream IMAC chromatography. 
Thus, after a gentle resuspension, the addition of DNAse is also not 
considered necessary. The exception is of course, when there is an un-
precedented amount of cell lysis, usually presenting as a slurry pellet 
after osmotic shock and centrifugation. 
Enhancement of the IMAC purification of the Nanobodies was also 
adopted in the improved protocol. This was done by reducing the IMAC 
column size to 0.5 mL of Ni-NTA slurry instead of 1 mL per liter of 
culture. This increased the specific attachment of the C-terminal Nano-
body hexa-histidine tag, instead of the bacterial contaminants with 
histidine stretches, due to their competitive affinity for the Ni2+ ions. As 
can be observed in the gel images presented, this resulted in a relatively 
pure protein with a prominent band at the expected size (about 15 kDa). 
Further improvements proposed for adoption to the modified protocol 
include adding imidazole (up to 20 mM) in the washing buffer to remove 
the high molecular weight bacterial contaminants observed in the IMAC 
elution and appearing early in SEC profile. 
Thermal shift analyses (TSA) using differential scanning fluorimetry 
(DSF) indicate that the extracted Nanobodies retained their character-
istics, giving similar thermal melt profiles as those derived using the 
standard procedures. This further enhanced our confidence that the 
procedures we applied did not result in a drastic change in the expressed 
product, despite there being a favorable change in yield. 
5. Conclusion 
Here, we demonstrate the yield enhancement from Nanobodies 
extracted from the periplasm by taking into consideration the biology of 
the expression host E. coli. Utilizing the temperature at which the E. coli 
Sec translocon operates most efficiently, we were able to reduce both the 
destruction of the selective antibiotic agent as well as enhance the 
periplasmic translocation of expressed Nanobodies. Using legacy 
extraction procedures derived from literature, into the standard pro-
duction protocol, allowed us to enhance the extraction and purification 
of the expressed Nanobodies by several fold. We therefore propose this 
modified protocol as a substitute for the expression of refractory 
Nanobodies. 
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